CL2018000278A1 - Derivados de etinilo - Google Patents
Derivados de etiniloInfo
- Publication number
- CL2018000278A1 CL2018000278A1 CL2018000278A CL2018000278A CL2018000278A1 CL 2018000278 A1 CL2018000278 A1 CL 2018000278A1 CL 2018000278 A CL2018000278 A CL 2018000278A CL 2018000278 A CL2018000278 A CL 2018000278A CL 2018000278 A1 CL2018000278 A1 CL 2018000278A1
- Authority
- CL
- Chile
- Prior art keywords
- cioxy
- lower rent
- rent
- halogen
- replaced
- Prior art date
Links
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- -1 PYRIMIDINYL Chemical class 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA I, DONDE R1 ES HIDRÓGENO, F O CL; L ES UN ENLACE O ALQUILENO INFERIOR; R2 ES -(CH2) N-ALQUILO INFERIOR, ALQUILO INFERIOR SUSTITUIDO POR HALÓGENO, -(CH2)NC(O)O-ALQUILO INFERIOR, FENILO SUSTITUIDO POR ALQUILO INFERIOR O HALÓGENO, O ES UN GRUPO HETEROARILO DE 5 O 6 MIEMBROS, SELECCIONADO ENTRE PIRIDINILO, PIRIMIDINILO, PIRIDAZINILO, TIAZOLILO, IMIDAZOLILO, PIRAZOLILO O TRIAZOLILO, QUE ESTÁN OPCIONALMENTE SUSTITUIDOS POR ALQUILO INFERIOR, HALÓGENO, ALCOXI INFERIOR, =O, BENCILOXI, CICLOALCOXI, HIDROXI, CIANO, ALQUILO INFERIOR SUSTITUIDO POR HALÓGENO, O POR -(CH2)N-ALQUILO INFERIOR; N ES 1, 2 O 3; R3 ES HIDRÓGENO, ALQUILO INFERIOR O -(CH2)N-ALQUILO INFERIOR; R4 ES FENILO, PIRIDINILO O PIRIMIDINILO, OPCIONALMENTE SUSTITUIDO POR F; Y ES CF O CCL; O A UNA SAL FARMACÉUTICAMENTE ACEPTABLE O SAL DE ADICIÓN ÁCIDA, A UNA MEZCLA RACÉMICA, O A SU CORRESPONDIENTE ENANTIÓMERO Y/O ISÓMERO ÓPTICO Y/O ESTEREOISÓMEROS DE LOS MISMOS. LOS COMPUESTOS SE PUEDEN USAR PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ANSIEDAD, EMESIS, TRASTORNO OBSESIVO COMPULSIVO, AUTISMO, NEUROPROTECCIÓN, CÁNCER, DEPRESIÓN Y LA DIABETES TIPO 2.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15179550 | 2015-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000278A1 true CL2018000278A1 (es) | 2018-07-06 |
Family
ID=53776452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000278A CL2018000278A1 (es) | 2015-08-03 | 2018-01-31 | Derivados de etinilo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10011607B2 (es) |
| EP (1) | EP3331882B1 (es) |
| JP (1) | JP6975511B2 (es) |
| KR (1) | KR20180030857A (es) |
| CN (1) | CN107667107B (es) |
| AR (1) | AR105556A1 (es) |
| AU (1) | AU2016302696B2 (es) |
| BR (1) | BR112017023951A2 (es) |
| CA (1) | CA2983908A1 (es) |
| CL (1) | CL2018000278A1 (es) |
| CO (1) | CO2017011010A2 (es) |
| HK (1) | HK1246790A1 (es) |
| IL (1) | IL255103B (es) |
| MX (1) | MX2018001486A (es) |
| PE (1) | PE20180357A1 (es) |
| PH (1) | PH12018500247A1 (es) |
| RU (1) | RU2722014C9 (es) |
| TW (1) | TWI621619B (es) |
| UA (1) | UA120888C2 (es) |
| WO (1) | WO2017021384A1 (es) |
| ZA (1) | ZA201707015B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA122148C2 (uk) | 2015-08-03 | 2020-09-25 | Гленмарк Фармасьютікалс С.А. | Сполуки як модулятори ror-гамма |
| WO2017023905A1 (en) | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as modulators of tnf alpha |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| EP3898588B1 (en) | 2018-12-21 | 2023-01-11 | Merck Patent GmbH | Disubstituted alkyne derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8912336B2 (en) * | 2009-11-06 | 2014-12-16 | Vanderbilt University | Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN103492374B (zh) * | 2011-04-26 | 2016-06-01 | 霍夫曼-拉罗奇有限公司 | 吡唑烷-3-酮衍生物 |
| SG11201602029VA (en) * | 2013-09-25 | 2016-04-28 | Hoffmann La Roche | Ethynyl derivatives |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| UA117855C2 (uk) * | 2014-02-25 | 2018-10-10 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу |
-
2016
- 2016-08-01 AR ARP160102335A patent/AR105556A1/es unknown
- 2016-08-02 CA CA2983908A patent/CA2983908A1/en not_active Abandoned
- 2016-08-02 AU AU2016302696A patent/AU2016302696B2/en not_active Ceased
- 2016-08-02 KR KR1020187003005A patent/KR20180030857A/ko not_active Ceased
- 2016-08-02 JP JP2018505431A patent/JP6975511B2/ja active Active
- 2016-08-02 CN CN201680029481.6A patent/CN107667107B/zh active Active
- 2016-08-02 MX MX2018001486A patent/MX2018001486A/es active IP Right Grant
- 2016-08-02 RU RU2018105872A patent/RU2722014C9/ru active
- 2016-08-02 UA UAA201801410A patent/UA120888C2/uk unknown
- 2016-08-02 WO PCT/EP2016/068359 patent/WO2017021384A1/en active Application Filing
- 2016-08-02 HK HK18106336.0A patent/HK1246790A1/zh unknown
- 2016-08-02 PE PE2017002405A patent/PE20180357A1/es unknown
- 2016-08-02 EP EP16745473.5A patent/EP3331882B1/en active Active
- 2016-08-02 TW TW105124484A patent/TWI621619B/zh not_active IP Right Cessation
- 2016-08-02 BR BR112017023951-5A patent/BR112017023951A2/pt not_active Application Discontinuation
-
2017
- 2017-10-17 ZA ZA2017/07015A patent/ZA201707015B/en unknown
- 2017-10-18 IL IL255103A patent/IL255103B/en active IP Right Grant
- 2017-10-27 CO CONC2017/0011010A patent/CO2017011010A2/es unknown
-
2018
- 2018-01-10 US US15/867,097 patent/US10011607B2/en active Active
- 2018-01-31 CL CL2018000278A patent/CL2018000278A1/es unknown
- 2018-02-01 PH PH12018500247A patent/PH12018500247A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016302696B2 (en) | 2020-05-07 |
| AU2016302696A1 (en) | 2017-11-02 |
| AR105556A1 (es) | 2017-10-18 |
| RU2722014C9 (ru) | 2020-10-22 |
| IL255103A0 (en) | 2017-12-31 |
| TW201718589A (zh) | 2017-06-01 |
| UA120888C2 (uk) | 2020-02-25 |
| IL255103B (en) | 2020-01-30 |
| TWI621619B (zh) | 2018-04-21 |
| EP3331882A1 (en) | 2018-06-13 |
| KR20180030857A (ko) | 2018-03-26 |
| HK1246790A1 (zh) | 2018-09-14 |
| CA2983908A1 (en) | 2017-02-09 |
| CN107667107A (zh) | 2018-02-06 |
| BR112017023951A2 (pt) | 2018-07-24 |
| EP3331882B1 (en) | 2020-04-29 |
| PH12018500247A1 (en) | 2018-08-13 |
| MX2018001486A (es) | 2018-03-15 |
| ZA201707015B (en) | 2018-11-28 |
| US20180127429A1 (en) | 2018-05-10 |
| JP2018522037A (ja) | 2018-08-09 |
| CN107667107B (zh) | 2021-05-18 |
| PE20180357A1 (es) | 2018-02-21 |
| WO2017021384A1 (en) | 2017-02-09 |
| US10011607B2 (en) | 2018-07-03 |
| RU2018105872A3 (es) | 2019-12-26 |
| JP6975511B2 (ja) | 2021-12-01 |
| RU2722014C2 (ru) | 2020-05-26 |
| CO2017011010A2 (es) | 2018-02-09 |
| RU2018105872A (ru) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000036A1 (es) | Derivados etinilo | |
| CL2018000278A1 (es) | Derivados de etinilo | |
| PE20160546A1 (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 | |
| PE20142282A1 (es) | Nuevos derivados de aril-quinolina | |
| CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| ECSP11010804A (es) | Compuestos orgánicos | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| AR099047A1 (es) | Derivados etinilo | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| BR112015005186A2 (pt) | 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc | |
| MY148301A (en) | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds | |
| MX385276B (es) | Tratamiento para la enfermedad de parkinson | |
| AR104331A1 (es) | Derivados de tetrazol | |
| AR097721A1 (es) | Derivados de etinilo | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
| AR074467A1 (es) | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| CO2018013824A2 (es) | Derivados de etinilo | |
| AR105327A1 (es) | Derivados de imidazol | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| AR107490A1 (es) | Derivados de pirazol-piridina como inhibidores de eaat3 | |
| AR093029A1 (es) | Derivados de etilino | |
| AR066086A1 (es) | Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida | |
| AR062412A1 (es) | Amidas con dos sustituyentes aromaticos como inhibidores del g1yt1 |